| Market Cap | 59.89M | P/E | - | EPS this Y | 15.70% | Ern Qtrly Grth | - |
| Income | -25.98M | Forward P/E | -2.18 | EPS next Y | 1.40% | 50D Avg Chg | -16.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -19.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -60.00% |
| Recommedations | 1.50 | Quick Ratio | 0.93 | Shares Outstanding | 34.51M | 52W Low Chg | 104.00% |
| Insider Own | 71.77% | ROA | -81.18% | Shares Float | 9.78M | Beta | - |
| Inst Own | 1.75% | ROE | -1,238.98% | Shares Shorted/Prior | 195.72K/287.95K | Price | 1.74 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 156,164 | Target Price | 8.33 |
| Oper. Margin | - | Earnings Date | Nov 3 | Volume | 81,447 | Change | 0.58% |
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It's product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.
| HC Wainwright & Co. | Buy | Aug 10, 23 |
| HC Wainwright & Co. | Buy | May 12, 23 |
| HC Wainwright & Co. | Buy | Apr 19, 23 |
| Evercore ISI Group | Outperform | Mar 22, 23 |
| HC Wainwright & Co. | Buy | Mar 22, 23 |
| HC Wainwright & Co. | Buy | Aug 10, 22 |
| B. Riley Securities | Buy | Jan 24, 22 |
| William Blair | Outperform | Nov 9, 21 |
| Evercore ISI Group | Outperform | Nov 9, 21 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| AGENUS INC | Director Director | Aug 29 | Buy | 1.5168 | 29,678 | 45,016 | 21,734,887 | 08/31/23 |
| AGENUS INC | 10% Owner 10% Owner | Aug 24 | Buy | 1.5 | 183,052 | 274,578 | 21,705,209 | 08/28/23 |
| AGENUS INC | Director Director | May 10 | Buy | 1.47 | 45,426 | 66,776 | 21,640,473 | 05/12/23 |
| ARMEN GARO H | Director Director | May 05 | Sell | 0.9485 | 100,000 | 94,850 | 1,866,400 | 05/05/23 |
| AGENUS INC | Director Director | May 03 | Buy | 1.12 | 250,362 | 280,405 | 21,595,047 | 05/05/23 |
| ARMEN GARO H | Director Director | May 02 | Buy | 0.9485 | 100,000 | 94,850 | 1,978,010 | 05/04/23 |
| WIINBERG ULF | Director Director | Jul 18 | Buy | 1.36 | 20,000 | 27,200 | 298,300 | 07/21/22 |
| AGENUS INC | 10% Owner 10% Owner | Oct 19 | Buy | 12 | 1,400,000 | 16,800,000 | 20,881,000 | 10/20/21 |